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term toxicity and efficacy data are clearly crucial and will be 
reported in due course. 
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Purpose/Objective: To evaluate the feasibility and toxicity 
of hypofractionated stereotactic body radiation therapy 
(SBRT) with volumetric modulated arc therapy (VMAT) and 
flattening filter-free (FFF) beams. 
Materials and Methods: A prospective designated phase I-II 
study was approved by our institutional review and ethics 
board (started in April 2013). Inclusion criteria were 
histologically proven prostate adenocarcinoma, Gleason Score 
6–7, clinical stage T1b–T2b, prostate-specific antigen (PSA) ≤ 
20 ng/mL, prostate volume ≤ 60 cc, no previous surgery, no 
malignant tumours in the previous 5 years, IPSS 0–7 Neo-
adjuvant/concomitant hormonal-therapy was prescribed 
according to risk classification. Image Guided RT with Cone 
Beam CT (with or without fiducial markers) is mandatory. 
Urinary catheter was needed to plan and deliver radiation in 
order to maintain bladder volume stable during treatment. 
SBRT was delivered at a prescribed planning target volume 
(PTV) dose of 35 Gy in five fractions in 5 alternative days 
using the TrueBeam with RapidArc VMAT, with 6 MV FFF 
photons. CTCAE v3.0 morbidity scores were used to assess 
toxicities. 
Results: A total of 11 patients have been recruited to date. 
Mean age of the patients was 71.2 years (range: 64–76 yr). 
Pathology centralized Gleason score was 6 in 6 patients and 7 
(3+4) in another five patients. Mean PSA was 9 ng/mL (range: 
0.03–17 ng/mL). According to D'Amico risk classification, 6/11 
patients were low-risk and 5/11 were intermediate risk. Mean 
prostate volume was 38.3 cc. All patients completed the 
treatment as programmed in 2 weeks and tolerated the 
treatment well. One haematuria related to renal colic and 
hypertensive crisis were observed in two different patients at 
the first session. Evaluating patients in a time period ranging 
from 3 to 18 months, no toxicity greater than grade 2 was 
observed. . Acute Toxicities were as follow: Rectum G0: 2/11 
cases (18.2%); G1: 5/11 (45.6%); G2: 4/11 (36.4%). Genito-
urinary: G1: 8/11 (72,3%); G2: 3/11 (27,3%). At 3 months 
follow-up toxicities were as follow: Rectum G0: 5/11 cases 
(45.6%); G1: 6/11 (54,5 %); G2: 1/11 (9.1%). Genito-urinary: 
G0: 4/11 (36.4%), G1: 6/11 (54.5 %); G2: 1/11 (9.1%).Test 
between average total IPSS at pre-entry when compared with 
1-month and 3-month evaluations showed a non-significant 
increase in mean value from 4 to 6. Biochemical response 
was seen at 3 month of follow-up with mean value of 2.1 
ng/ml (range from 0.03 to 5.89). 
Conclusions: Early findings indicate that SBRT with VMAT and 
FFF beams for low–intermediate-risk prostate cancer 
delivered in five fractions is feasible and well tolerated in 
selected patients. Long-term follow-up is needed for 
assessment of late toxicity and outcomes. 
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Purpose/Objective: Anterior rectal wall (ARW) receives 
inevitable high radiation dose in prostate cancer 
radiotherapy. The rectum-protective effect of endorectal 
ballooning (ERB) was assessed in terms of separate anatomic 
categorization focusing ARW and its dose distribution.  
Materials and Methods: Between Aug 2012 and Mar 2014, 
thirty one patients received curative tomotherapy for 
prostate cancer treatment. All treatment sessions were 
performed by intensity-modulated simultaneous integrated 
boost method to each target volume with customized 60 mL 
air balloon inserted into the rectum. The prescription dose 
was 70.0 Gy, 60.2 Gy, and 50.4 Gy to each planning target 
volume (PTV) for prostate gland (PG), seminal vesicles, and 
elective pelvic lymph node area with 28 fractionations, 
respectively. The ARW and posterior rectal wall (PRW) were 
contoured separately with 5 mm-thickness through the ERB-
inflated rectum area. In thirteen patients (49.1%, Group 1), 
PRW dose was restricted to maximum 40 Gy without ARW 
dose fixing. The other 18 patients (58.1%, Group 2) were 
treated by conventional dose constraint without additional 
dose condition to PRW area.  
Results: All patients completed their scheduled radiotherapy 
courses. The PG PTV dose distribution did not differ between 
the two groups (p = 0.694). The median PG PTV volume was 
46.5 mL (range, 15.9 - 127.2 mL), and its mean dose, D1%, V95% 
was 70.8 ± 0.65 Gy, 72.1 Gy, 69.8%, respectively. The 
overlapped volume between PG PTV and ARW was 13.4 mL. 
The mean dose and conformity index (V95%/VPG PTV) did not 
show significant difference between the two groups 
(p=0.405). The average dose, D1%, D50%, D70%, V20Gy, and V40Gy 
for ARW were not significantly different between the two 
groups. However, V60Gy had a tendency to be higher in Group 
1 (p=0.087). Acute rectal and urinary toxicities occurred in 4 
patients (12.9%) and 23 patients (74.2%), respectively, 
without Grade 3 or higher toxicity in both groups. No 
significant difference in rectal (p>0.999) and urinary 
(p=0.592) toxicity was showed between the two groups. 
Conclusions: Proper dose constraint to PRW showed tolerable 
acute toxicity profile without compromising PG PTV 
conformity despite the risk of high dose distribution to ARW 
area. However, radiobiological analysis may be required 
together with dose-volume approach in this relative 
conservative dose constraint condition. 
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Purpose/Objective: To evaluate the impact of clinical and 
dosimetric risk factors on acute gastrointestinal (GI) and 
genitourinary (GU) toxicity during hypofractionated intensity-
modulated radiotherapy (IMRT) in patients with prostate 
cancer. 
Materials and Methods: Between May 2009 and August 2014, 
195 patients with prostate cancer and negative lymph nodes 
underwent IMRT. Median age was 74 years (range 57-85). 
Disease stage: T1a in 3 patients (1.54%), T1b in 2 (1.03%), 
T1c in 28 (14.36%), T2a in 21 (10.77%), T2b in 36 (18.46%), 
T2c in 83 (42.56%), T3a in 9 (4.62%), T3b in 13 (6.67%); 
Gleason scores were 2- 6 in 114 patients (58.47 %),7 in 55 
(28.21 %) and 8-10 in 26 (13.34%). Median basal PSA was 8.1 
ng/ml (range 1.6-42.59 ng/ml). 107/195 patients (54.87%) 
received hormonal therapy (LHRH analogue and/or 
antiandrogen). IMRT was delivered with 15 MV photons. 
Planning target volume (PTV) consisted of CTV plus 1 cm in 
all directions except at the prostate-rectal interface where 
the margin was 0.5 cm. A hypofractionated regimen delivered 
a prescribed dose of 74.25 Gy in 33 fractions (2.25 
Gy/fraction) to the prostate and, if involved, to the seminal 
vescicles (SV). When the risk of SV involvement was >15% 
according Roach’s formula SV received 62 Gy in 33 fractions 
(1.879 Gy/fraction) using a simultaneous integrated boost 
(SIB-IMRT) . Median prostate volume was 43.93 cm3 (range 
16.72-161.60 cm3). Acute toxicity was scored using Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0.  
Results: At median follow-up of 26 months (range 3-60) acute 
genitourinary (GU) toxicity was observed in 140 (71.80%) 
patients: G1 in 81 (41.54%), G2 in 49 (25.13%), G3 in 10 
(5.13%). Acute gastrointestinal (GI) toxicity, consisting mainly 
of proctitis, was observed in 79 (40.51%) patients: G1 in 44 
(22.56%), G2 in 33 patients (16.92 %), G3 in 2 patients 
(1.03%). There was no G4 acute GU or GI toxicity. 
Administration of 3-OH-Methylglutaryl CoA reductase 
inhibitors (statins) significantly reduced the GI toxicity rate 
and grade (p =0.028 and p =0.029 respectively; Chi-Square 
test). Large prostate volume was associated with a higher 
rate and grade of acute GU toxicity (p = 0.02 Mann-Whitney 
test and p = 0.003 Spearman’s correlation). Bladder V50 
correlated with a higher grade of acute GU toxicity (p =0.038 
Spearman’s correlation) . GU and GI toxicities rate and grade 
were strongly interrelated (p =0.000; Chi-Square test). 
Conclusions: Hypofractionated IMRT for prostate cancer is 
safe and is associated with low acute toxicities. A large pre-
treatment prostate volume was associated with increased GU 
toxicity. We hypothesized that statins use might lower the 
incidence of GI toxicity. During treatment planning bladder 
V50 should be reduced in order to avoid GU toxicity. 
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Purpose/Objective: To study bladder filling in patients 
receiving external beam radiotherapy (EBRT) for 
gynaecological cancer and its impact on target coverage. 
Cervical and endometrial cancers are the most common 
gynaecological cancers treated with EBRT. At radiotherapy 
planning we aim for a ‘comfortably full bladder’in an attempt 
to move small bowel out of the pelvis and thereby minimise 
irradiated bowel volume. In an ideal scenario the bladder 
volume would be identical during each treatment fraction. 
This would also minimise organ position variation. There is 
limited data regarding bladder filling variation and its impact 
on target volume coverage in gynaecological cancers.This 
study attempts to quantify the impact of variation in bladder 
filling on target coverage. 
Materials and Methods: 12 patients underwent twice weekly 
cone beam computed tomography (CBCT) scans during 3D 
conformal radiotherapy for gynaecological cancer. 
Retrospective analysis of CBCT's was performed. All were 
planned with a ‘comfortably full bladder’. The standard 
protocol is to drink 600ml of water, 30 minutes before 
scanning or treatment. Actual bladder filling times were 
recorded. The bladder, rectum and clinical target volume 
(CTV) for each patient were contoured on the CBCT using 
Eclipse v11.  Bladder volume and CTV position in relation to 
planning target volume (PTV) was calculated and compared 
with the planning CT. 
Results: 12 patients were analysed; 5 received adjuvant 
radiotherapy for endometrial cancer and 7 received radical 
chemo-radiotherapy for cervical cancer. 130 CBCTs were 
taken and analysed using Offline Review ARIA v11. Significant 
variation in bladder volume is seen throughout treatment and 
between patients despite identical drinking instructions. A 
decrease in bladder volume is seen as treatment progresses 
(approx. 4cc per day). True waiting times vary with only 45% 
of patients fulfilling the planned waiting time +/-5minutes. 
Bladder filling impacts CTV position in cervical cancer due to 
uterine movement. A deviation >150cc from planning volume 
led to the superior anterior uterus extending outside of the 
PTV in all cases, however the CTV remained within the 
treatment field. The largest impact is seen if the bladder 
volume is large (>300mls) at planning. No significant impact 
is seen in post-operative patients.  
Conclusions: Accurate bladder filling minimises daily organ 
position variation and reduces the risk of geographical misses 
in cervical cancer. Clinically significant variation occurs 
despite strict drinking protocols. Systematic reduction 
throughout the treatment course is seen for both cervical and 
endometrial patients. We propose an optimal bladder volume 
range (150-300ml) which should be adhered to at the 
planning stage. We also recommend strict monitoring during 
